摘要
大麻受体1(CB1-R)属于G-蛋白耦联受体超家族成员,主要分布于中枢神经系统。选择性的CB1受体阻滞剂通过作用该受体,具有治疗肥胖、酒精依赖、尼古丁成瘾、认知障碍以及胃肠道系统疾病等作用。目前,已发现有许多二芳基吡唑类和基于此类化合物衍生出来的多种类型化合物表现出较高的选择性和较好的阻断活性。现综述该类药物的作用机制、结构修饰和构效关系。
Cannabinoid receptor-1 (CB1-R) is one of the G-protein coupled receptors, and it is expressed predominantly in the central nervous system. Selective CB1-R antagonists have potential in the treatment of a number of diseases, such as obesity, alcohol dependence, nicotine addiction, cognitive disorders, and gastrointestinal disorders. Recent studies found that many diphenylpyrazoles and other derivated compounds have good CBj-R selectivity and antagonistic activity. In this review, the mechanism, structural modifications and structure-activity relationship of CB1-R antagonists are summarized.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2008年第6期450-455,共6页
Chinese Journal of New Drugs
关键词
大麻受体1
阻滞剂
利莫那班
构效关系
cannabinoid receptor-1
antagonists
rimonabant
structure-activity relationship